I trained both as a scientist and as a physician and, throughout my career, I have focused on the treatment and biology of ovarian cancer (OvCa). My Ph.D. thesis was on the role of proteases in ovarian cancer and my clinical fellowship involved a special emphasis on the treatment of patients with this disease. As a surgeon and clinician, I am familiar with the presentation of ovarian cancer in patients, and experience the incredible obstacles we face in its treatment. In the laboratory, I have built the research infrastructure necessary for effective ovarian cancer research.
The Lengyel lab has elucidated, at least in part, the first critical steps of ovarian cancer metastasis by paying close attention to the host microenvironment. We have collected the 25 most commonly used ovarian cancer cell lines from all over the world, including those which are chemotherapy resistant. We have established several mouse models for OvCa, and using a genetic mouse model (K-rasG12D/+/Pten-/- -- established by Dr. Tyler Jacks), a syngeneic orthotopic mouse model using mouse OvCa cells (ID8 -- established by K. Roby), and several xenograft ip models using primary and cultured human OvCa cells. I have also established a prospective OvCa tissue bank and, together with 2 gynecologic pathologists, we have assembled 13 tissue arrays including normal tissue, borderline tumor and primary tumor, & corresponding metastasis. As a surgeon, the main focus of my practice is patients with OvCa; therefore, I will be able to enroll a substantial number of patients on the proposed clinical trial and have the infrastructure in place to collect the tissue required for the translational studies.
My clinical experience treating ovarian cancer, together with my laboratory, which focuses on OvCa biology, gives me a unique opportunity and obligation to find new treatments that can benefit patients with ovarian cancer.
University of Munich
Munich
M.D. - M.D.
1992
Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis.
Cui C, Chakraborty K, Tang XA, Zhou G, Schoenfelt KQ, Becker KM, Hoffman A, Chang YF, Blank A, Reardon CA, Kenny HA, Vaisar T, Lengyel E, Greene G, Becker L. Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell. 2021 Jun 10; 184(12):3163-3177.e21.
PMID: 33964209
Change in Health-Related Socioeconomic Risk Factors and Mental Health During the Early Phase of the COVID-19 Pandemic: A National Survey of U.S. Women.
Lindau ST, Makelarski JA, Boyd K, Doyle KE, Haider S, Kumar S, Lee NK, Pinkerton E, Tobin M, Vu M, Wroblewski KE, Lengyel E. Change in Health-Related Socioeconomic Risk Factors and Mental Health During the Early Phase of the COVID-19 Pandemic: A National Survey of U.S. Women. J Womens Health (Larchmt). 2021 04; 30(4):502-513.
PMID: 33818123
Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
Kurnit KC, Fleming GF, Lengyel E. Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. Obstet Gynecol. 2021 01 01; 137(1):108-121.
PMID: 33278287
Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
Kurnit KC, Fleming GF, Lengyel E. Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. Obstet Gynecol. 2020 Dec 03.
PMID: 33278287
Deconstructing tumor heterogeneity: the stromal perspective.
Vickman RE, Faget DV, Beachy P, Beebe D, Bhowmick NA, Cukierman E, Deng WM, Granneman JG, Hildesheim J, Kalluri R, Lau KS, Lengyel E, Lundeberg J, Moscat J, Nelson PS, Pietras K, Politi K, Puré E, Scherz-Shouval R, Sherman MH, Tuveson D, Weeraratna AT, White RM, Wong MH, Woodhouse EC, Zheng Y, Hayward SW, Stewart SA. Deconstructing tumor heterogeneity: the stromal perspective. Oncotarget. 2020 Oct 06; 11(40):3621-3632.
PMID: 33088423
Complete Response in a Patient With Chemorefractory EGFR-Amplified, PD-L1-Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Anti-PD-1 Monoclonal Antibody Therapy.
Reizine N, Peterson B, Moya S, Wang Y, Tan YCYH, Eng OS, Bilimoria M, Lengyel E, Turaga K, Catenacci DVT. Complete Response in a Patient With Chemorefractory EGFR-Amplified, PD-L1-Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Anti-PD-1 Monoclonal Antibody Therapy. JCO Precis Oncol. 2020; 4.
PMID: 33215053
Healthy food for trainees: a call to action.
Sackeim MG, Lengyel E. Healthy food for trainees: a call to action. Postgrad Med J. 2020 Aug 20.
PMID: 32820089
Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer?
Alter R, Turaga K, Lengyel E. Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer? JAMA Netw Open. 2020 08 03; 3(8):e2014184.
PMID: 32840618
Interpretation of Mismatch Repair Protein Immunohistochemistry in Endometrial Carcinoma Should Consider Both Lynch Syndrome Screening and Immunotherapy Susceptibility: An Illustrative Case Report.
Chapel DB, Lengyel E, Ritterhouse LL, Lastra RR. Interpretation of Mismatch Repair Protein Immunohistochemistry in Endometrial Carcinoma Should Consider Both Lynch Syndrome Screening and Immunotherapy Susceptibility: An Illustrative Case Report. Int J Gynecol Pathol. 2020 May; 39(3):233-237.
PMID: 30807370
A streamlined mass spectrometry-based proteomics workflow for large-scale FFPE tissue analysis.
Coscia F, Doll S, Bech JM, Schweizer L, Mund A, Lengyel E, Lindebjerg J, Madsen GI, Moreira JM, Mann M. A streamlined mass spectrometry-based proteomics workflow for large-scale FFPE tissue analysis. J Pathol. 2020 05; 251(1):100-112.
PMID: 32154592